



Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Member: Hussein Tawbi, M.D., Ph.D.

Committee: Cellular, Tissue, and Gene Therapies Advisory Committee

Meeting Date: July 30, 2026

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item described below, I may be considered for participation in the advisory committee meeting described below.

On July 30, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec. The proposed indication (use) is in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD-1 containing regimen.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
N/A		
II. Other Imputed Interests		
Employer's Contract	SGE's employing institution is a participating site in the clinical trial studying the sponsor's product under review	Undisclosed

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/s/
Signature

July 28, 2026
Date

Hussein Tawbi, M.D., Ph.D.